Eurobio Oncology jobs and careers

About Eurobio Oncology

Starting August 1st, EndoPredict, a genomic test for breast cancer patients, and Prolaris Kits, a prognostic test for prostate cancer patients, are joining the Eurobio Scientific portfolio. As a leading player in Molecular Diagnostics and Life Sciences, we are thrilled to expand our offer and enhance our commitment to innovative patient care. About Eurobio Scientific Eurobio Scientific is committed to enhancing patients' quality of life through innovative diagnostics. Our vision is to become a global leader in specialty diagnostics, offering cutting-edge solutions to healthcare professionals. With over 370 employees worldwide, we provide robust local support through our manufacturing and research centers, as well as offices in Europe, the USA, and a network of trusted distributors globally. Our expert R&D team focuses on developing advanced molecular diagnostic tests in oncology, transplant, and infectious diseases. About EndoPredict and Prolaris Kit EndoPredict: EndoPredict is a second generation genomic test for breast cancer that provides a thorough analysis of tumor biology. It helps predict the likelihood of cancer recurrence and chemotherapy benefit to support more informed decisions about adjuvant chemotherapy for patients with ER+, HER2- early-stage breast cancer. With its high prognostic accuracy, EndoPredict enables personalized treatment planning, ensuring that patients receive the most appropriate care based on their individual risk profile. Prolaris: Prolaris is a prognostic test for prostate cancer that measures the expression levels of genes involved in cell cycle progression. It provides an accurate assessment of the aggressiveness of prostate cancer, helping to distinguish between indolent and aggressive disease. Prolaris aids in risk stratification and guides treatment decisions, allowing clinicians to tailor their approach to each patient's specific cancer biology and risk of progression.